Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 3;22(4):1522.
doi: 10.3390/ijms22041522.

Thanatin: An Emerging Host Defense Antimicrobial Peptide with Multiple Modes of Action

Affiliations
Review

Thanatin: An Emerging Host Defense Antimicrobial Peptide with Multiple Modes of Action

Rachita Dash et al. Int J Mol Sci. .

Abstract

Antimicrobial peptides (AMPs) possess great potential for combating drug-resistant bacteria. Thanatin is a pathogen-inducible single-disulfide-bond-containing β-hairpin AMP which was first isolated from the insect Podisus maculiventris. The 21-residue-long thanatin displays broad-spectrum activity against both Gram-negative and Gram-positive bacteria as well as against various species of fungi. Remarkably, thanatin was found to be highly potent in inhibiting the growth of bacteria and fungi at considerably low concentrations. Although thanatin was isolated around 25 years ago, only recently has there been a pronounced interest in understanding its mode of action and activity against drug-resistant bacteria. In this review, multiple modes of action of thanatin in killing bacteria and in vivo activity, therapeutic potential are discussed. This promising AMP requires further research for the development of novel molecules for the treatment of infections caused by drug resistant pathogens.

Keywords: antimicrobial peptides (AMPs); lipopolysaccharide (LPS); mechanism of AMPs; multidrug-resistant (MDR) bacteria; thanatin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Amino acid sequences of thanatin and brevinin-1. The central Thr residue in the disulfide loop of thanatin is highlighted in green. Cys residues are indicated in blue.
Figure 2
Figure 2
Structures of thanatin in lipopolysaccharide (LPS, pdb:5xo9) and dodecyl phosphocholine (DPC) (pdb: 6aab) micelles. Thanatin forms a dimeric structure in LPS micelles. The side chains of (A) Y10/Y10′, M21/M21′, and (B) I9/I9′ demonstrated packing interactions in the antiparallel β-sheet topology. (C) Electrostatic potential surface of dimeric thanatin. (D) Monomeric β-hairpin structure of thanatin in DPC micelles. The β-sheet is shown as a ribbon. The figure was prepared using PyMOL.
Figure 3
Figure 3
Molecular dynamics (MD) simulation of the interactions between LPS and thanatin. Left panel: time course of the binding of thanatin to LPS in a bilayer observed in the simulation. Right panel: interactions of residues of thanatin with LPS head groups [27].
Figure 4
Figure 4
Structure (pdb: 6GD5) of thanatin in complex with LptAm: (A) The 3-D topology of the complex showing the β-sheet jelly-roll fold (purple) of LptAm and the β-hairpin of thanatin (in green). The side chains of residues of thanatin are shown as sticks. (B) Potential ionic interactions of residues R13 and R14 of thanatin with residues E39 and D41 of LptAm. (C) Packing interactions of residues Y10, I8 of thanatin with hydrophobic-pocket residues F54 and V70 of LptAm.

Similar articles

Cited by

References

    1. O’Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance (AMR), 2016. Government of the United Kingdom: Wellcome Trust U.K. [(accessed on 2 February 2021)]; Available online: https://www.biomerieuxconnection.com/wp-content/uploads/2018/04/Tackling....
    1. Rudd K.E., Johnson S.C., Agesa K.M., Shackelford K.A., Tsoi D., Kievlan D.R., Colombara D.V., Ikuta K.S., Kissoon N., Finfer S., et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: Analysis for the global burden of disease study. Lancet. 2020;395:200–211. doi: 10.1016/S0140-6736(19)32989-7. - DOI - PMC - PubMed
    1. Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M., Bellomo R., Bernard G.R., Chiche J.-D., Coopersmith C.M., et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3) JAMA. 2016;315:801–810. doi: 10.1001/jama.2016.0287. - DOI - PMC - PubMed
    1. Theuretzbacher U. Global antimicrobial resistance in gram-negative pathogens and clinical need. Curr. Opin. Microbiol. 2017;39:106–112. doi: 10.1016/j.mib.2017.10.028. - DOI - PubMed
    1. Tucker A.T., Leonard S.P., DuBois C.D., Knauf G.A., Cunningham A.L., Wilke C.O., Trent M.S., Davies B.W. Discovery of next-generation antimicrobials through bacterial self-screening of surface-displayed peptide libraries. Cell. 2018;172:618–628. doi: 10.1016/j.cell.2017.12.009. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources